Ieq Capital LLC Buys New Shares in Kura Oncology, Inc. $KURA

Key Points

• Ieq Capital LLC acquired a new stake in Kura Oncology by purchasing 97,931 shares valued at approximately $646,000, representing around 0.11% ownership.
• Several institutional investors, including Wells Fargo and Dimensional Fund Advisors, significantly increased their holdings in Kura Oncology during the fourth quarter.
• Kura Oncology recently missed earnings estimates, reporting a loss of ($0.75) per share and revenue of $15.29 million, which fell short of the consensus estimate of $64.95 million.

Ieq Capital LLC bought a new position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 97,931 shares of the company's stock, valued at approximately $646,000. Ieq Capital LLC owned approximately 0.11% of Kura Oncology as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Pallas Capital Advisors LLC bought a new position in Kura Oncology during the 1st quarter valued at approximately $66,000. Flower City Capital bought a new position in Kura Oncology during the 1st quarter valued at approximately $79,000. E Fund Management Co. Ltd. increased its position in Kura Oncology by 18.9% during the 1st quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company's stock valued at $81,000 after buying an additional 1,951 shares in the last quarter. Corton Capital Inc. bought a new position in Kura Oncology during the 4th quarter valued at approximately $99,000. Finally, Exchange Traded Concepts LLC increased its position in Kura Oncology by 117.8% during the 1st quarter. Exchange Traded Concepts LLC now owns 17,474 shares of the company's stock valued at $115,000 after buying an additional 9,450 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wall Street Zen raised Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Guggenheim initiated coverage on Kura Oncology in a research note on Thursday, September 4th. They set a "neutral" rating on the stock. JMP Securities cut their target price on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research note on Monday, August 11th. Finally, Mizuho cut their target price on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, May 19th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Kura Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.10.

Kura Oncology Stock Performance

Shares of KURA stock traded down $0.21 on Tuesday, reaching $7.94. The stock had a trading volume of 272,803 shares, compared to its average volume of 1,458,291. The stock has a market cap of $688.76 million, a P/E ratio of -3.52 and a beta of 0.19. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $21.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The company has a 50 day simple moving average of $6.71 and a 200 day simple moving average of $6.56.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million during the quarter, compared to the consensus estimate of $64.95 million. Equities research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.